Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Reversal of Complete Heart Block With Aminophylline in Inferior Wall Myocardial Infarction Patients
NCT05666219 · National Institute of Cardiovascular Diseases, Pakistan · PHASE4 · withdrawn · last registry update 2025-05-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “we could not find patients fulfilling all of our inclusion criteria” | – | Registry record, National Institute of Cardiovascular Diseases, Pakistan |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE4A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-30Phase 3 first posted: Beni-Suef University, pentoxifylline 400 mg (NCT07499817)
- 2025-09-30Phase 3 first posted: Yunfeng Xia, Dipyridamole 50mg tid (NCT07199504)
- 2025-08-20Results posted on the registry: Washington University School of Medicine, theophylline + Placebo (NCT05947643)
- 2025-06-11Results posted on the registry: Al-Azhar University, combination of Pentoxifylline 400 MG and Folic Acid + folic acid (NCT05284656)
- 2025-06-08Phase 3 first posted: Hany Mohammed El-Hadi Shoukat Mohammed, Group (E): receive aminophylline early intraoperatively, + Group (L) received aminophylline late intraoperatively (NCT07011134)
- 2025-05-31Also stopped (withdrawn): Cedars-Sinai Medical Center, Pentoxifylline Oral Product + Placebo (NCT04391231)
- 2025-05-29Also stopped (withdrawn): Wake Forest University Health Sciences, Otezla - Standard Care (NCT05601492)
- 2025-05-22Also stopped (terminated): Prokrea BCN, S.L., Vaginal product (NCT06986031)
- 2025-04-18Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine 3 mg twice daily (NCT06460493)
- 2025-04-13Results posted on the registry: Bristol-Myers Squibb, Deucravacitinib + Apremilast (NCT04908189)
- 2025-04-09Results posted on the registry: Amgen, Apremilast + Placebo (NCT05174065)
- 2025-03-13Also stopped (withdrawn): University of Nebraska, CYR-064 (NCT06498687)
- 2025-03-07Phase 3 first posted: SFA Therapeutics, SFA002 + Otezla (NCT06863493)
- 2025-02-21Results posted on the registry: Rutgers, The State University of New Jersey, Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (NCT04410328)
- 2024-11-27Results posted on the registry: University of California, Los Angeles, Ibudilast + Placebo oral capsule (NCT03594435)
- 2024-10-30Results posted on the registry: MediciNova, Ibudilast + Placebo (NCT04429555)
- 2024-10-29Results posted on the registry: University of Miami, Theophylline ER + Placebo oral tablet (NCT03984188)
- 2024-10-15Results posted on the registry: University of Missouri-Columbia, Pentoxifylline + Placebo (NCT02592863)
- 2024-10-15Also stopped (terminated): University of Missouri-Columbia, Pentoxifylline + Placebo (NCT02592863)
- 2024-10-01Results posted on the registry: Philips Clinical & Medical Affairs Global, a drug against PDE4A (NCT04696354)
- 2024-09-25Also stopped (terminated): Iain Bressendorff, ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib (NCT05897372)
- 2024-09-24Results posted on the registry: MediciNova, ibudilast + Ibudilast (NCT02714036)
- 2024-09-19Phase 3 first posted: Alumis Inc, Envudeucitinib + Placebo (NCT06588738)
- 2024-09-19Phase 3 first posted: Alumis Inc, Envudeucitinib + Apremilast (NCT06586112)
- 2024-06-14Phase 3 first posted: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine 3 mg twice daily (NCT06460493)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision